Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cullinan Oncology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CGEM
Nasdaq
8731
https://www.cullinanoncology.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cullinan Oncology Inc
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Nov 8th, 2023 12:00 pm
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
- Nov 3rd, 2023 4:01 pm
Cullinan Oncology to Participate in Upcoming Investor Conferences
- Oct 30th, 2023 12:00 pm
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Aug 10th, 2023 11:00 am
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Aug 9th, 2023 11:00 am
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
- Aug 3rd, 2023 8:15 pm
Why Shares of Cullinan Oncology Jumped This Week
- Jun 9th, 2023 8:07 pm
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
- May 25th, 2023 9:00 pm
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
- May 11th, 2023 8:01 pm
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
- Apr 26th, 2023 2:08 pm
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
- Apr 20th, 2023 11:00 am
12 Cheap Healthcare Stocks to Buy in 2023
- Mar 29th, 2023 2:13 pm
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
- Mar 27th, 2023 11:00 am
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
- Mar 14th, 2023 8:35 pm
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Mar 9th, 2023 12:00 pm
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
- Feb 27th, 2023 1:00 pm
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
- Feb 14th, 2023 12:00 am
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
- Feb 2nd, 2023 9:01 pm
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 1st, 2023 9:42 pm
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Jan 24th, 2023 1:00 pm
Scroll